What Causes Vaginal Itching in Women—and How to Treat It

Genital itching in women—medically termed pruritus vulvae—is not a disease itself but rather a common symptom with a wide range of potential underlying causes. It reflects irritation, inflammation, or dysfunction affecting the vulvar skin and mucosa, and may be acute or chronic (persisting for six weeks or longer). Accurate diagnosis requires careful clinical evaluation, as treatment depends entirely on identifying the root cause.

Common infectious triggers include vulvovaginal candidiasis (often caused by *Candida albicans*), bacterial vaginosis, and trichomoniasis. Sexually transmitted infections such as genital herpes (HSV-2), syphilis, and pubic lice (*Pthirus pubis*) can also present with prominent pruritus. Non-infectious contributors are equally prevalent: lichen sclerosus—a chronic inflammatory dermatosis associated with white plaques, skin fragility, and increased risk of squamous cell carcinoma—frequently manifests with severe, persistent itching. Lichen planus and psoriasis may involve the vulva as part of broader cutaneous disease. Contact irritant or allergic dermatitis, often linked to soaps, detergents, scented hygiene products, or topical medications, is another frequent culprit.

Hormonal changes play a significant role, particularly in hypoestrogenic states. Vulvovaginal atrophy—formerly known as atrophic vaginitis—commonly occurs during perimenopause, postmenopause, or following surgical oophorectomy or certain cancer treatments. Reduced estrogen leads to thinning, dryness, and loss of elasticity in vulvovaginal tissues, resulting in pruritus, dyspareunia, and sometimes fissuring or bleeding. Less common but important considerations include extramammary Paget disease (a rare intraepidermal adenocarcinoma), vulvar intraepithelial neoplasia (VIN), and, rarely, invasive vulvar carcinoma—especially when itching is unilateral, refractory to treatment, or accompanied by ulceration, induration, or pigmented lesions.

Management begins with a thorough history—including symptom duration, hygiene practices, product use, sexual history, and systemic symptoms—and a meticulous physical examination, ideally with good lighting and gentle retraction of labial folds. Diagnostic testing may include wet mount microscopy, vaginal pH measurement, fungal culture or PCR testing, and, when indicated, biopsy of suspicious lesions. Empiric antifungal therapy is appropriate only if clinical features strongly suggest candidiasis; inappropriate or repeated use of antifungals can mask other conditions and promote resistance.

Treatment is etiology-specific: topical antifungals for confirmed candidiasis; metronidazole or clindamycin for bacterial vaginosis; antivirals for herpes; and permethrin or oral ivermectin for pediculosis. For lichen sclerosus, first-line therapy is high-potency topical corticosteroids (e.g., clobetasol propionate 0.05%) applied intermittently under supervision to minimize atrophy risk. Hormone therapy—either low-dose vaginal estrogen tablets, creams, or rings—is highly effective for vulvovaginal atrophy. Patient education on vulvar hygiene is critical: avoidance of harsh cleansers, tight synthetic clothing, and douching; use of fragrance-free, hypoallergenic products; and application of emollients like plain petroleum jelly for barrier support.

Women experiencing persistent, worsening, or recurrent vulvar itching—particularly those over age 45 or with unexplained skin changes—should seek prompt gynecologic or dermatologic evaluation. Early diagnosis not only alleviates distressing symptoms but also enables timely intervention for potentially premalignant or malignant conditions.